<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37239468</PMID><DateCompleted><Year>2023</Year><Month>05</Month><Day>29</Day></DateCompleted><DateRevised><Year>2023</Year><Month>05</Month><Day>31</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2073-4425</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>5</Issue><PubDate><Year>2023</Year><Month>May</Month><Day>18</Day></PubDate></JournalIssue><Title>Genes</Title><ISOAbbreviation>Genes (Basel)</ISOAbbreviation></Journal><ArticleTitle>Generation of an Open-Access Patient-Derived iPSC Biobank for Amyotrophic Lateral Sclerosis Disease Modelling.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1108</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/genes14051108</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease affecting the upper and lower motor neurons, causing patients to lose control over voluntary movement, and leading to gradual paralysis and death. There is no cure for ALS, and the development of viable therapeutics has proved challenging, demonstrated by a lack of positive results from clinical trials. One strategy to address this is to improve the tool kit available for pre-clinical research. Here, we describe the creation of an open-access ALS iPSC biobank generated from patients carrying mutations in the <i>TARDBP</i>, <i>FUS</i>, <i>ANXA11</i>, <i>ARPP21</i>, and <i>C9ORF72</i> genes, alongside healthy controls. To demonstrate the utilisation of these lines for ALS disease modelling, a subset of <i>FUS</i>-ALS iPSCs were differentiated into functionally active motor neurons. Further characterisation revealed an increase in cytoplasmic FUS protein and reduced neurite outgrowth in <i>FUS</i>-ALS motor neurons compared to the control. This proof-of-principle study demonstrates that these novel patient-derived iPSC lines can recapitulate specific and early disease-related ALS phenotypes. This biobank provides a disease-relevant platform for discovery of ALS-associated cellular phenotypes to aid the development of novel treatment strategies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hedges</LastName><ForeName>Erin C</ForeName><Initials>EC</Initials><Identifier Source="ORCID">0000-0002-2519-9824</Identifier><AffiliationInfo><Affiliation>United Kingdom Dementia Research Institute, Maurice Wohl Clinical Neuroscience Institute, Institute of Psychiatry, Psychology and Neuroscience, King's College London, 5 Cutcombe Rd., London SE5 9RT, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cocks</LastName><ForeName>Graham</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Genome Editing and Embryology Core, King's College London, London SE1 1UL, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shaw</LastName><ForeName>Christopher E</ForeName><Initials>CE</Initials><AffiliationInfo><Affiliation>United Kingdom Dementia Research Institute, Maurice Wohl Clinical Neuroscience Institute, Institute of Psychiatry, Psychology and Neuroscience, King's College London, 5 Cutcombe Rd., London SE5 9RT, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Brain Research, University of Auckland, 85 Park Road, Grafton, Auckland 1023, New Zealand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nishimura</LastName><ForeName>Agnes L</ForeName><Initials>AL</Initials><Identifier Source="ORCID">0000-0001-5295-797X</Identifier><AffiliationInfo><Affiliation>United Kingdom Dementia Research Institute, Maurice Wohl Clinical Neuroscience Institute, Institute of Psychiatry, Psychology and Neuroscience, King's College London, 5 Cutcombe Rd., London SE5 9RT, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Blizard Institute, Neuroscience, Surgery and Trauma, Queen Mary University of London, 4 Newark Street, London E1 2AT, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>05</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Genes (Basel)</MedlineTA><NlmUniqueID>101551097</NlmUniqueID><ISSNLinking>2073-4425</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057026" MajorTopicYN="Y">Induced Pluripotent Stem Cells</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="Y">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018070" MajorTopicYN="N">Biological Specimen Banks</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">biobank</Keyword><Keyword MajorTopicYN="N">disease modelling</Keyword><Keyword MajorTopicYN="N">induced pluripotent stem cell</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>4</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>5</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>5</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>29</Day><Hour>6</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>5</Month><Day>27</Day><Hour>9</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>27</Day><Hour>1</Hour><Minute>11</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37239468</ArticleId><ArticleId IdType="pmc">PMC10218399</ArticleId><ArticleId IdType="doi">10.3390/genes14051108</ArticleId><ArticleId IdType="pii">genes14051108</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Takahashi K., Tanabe K., Ohnuki M., Narita M., Ichisaka T., Tomoda K., Yamanaka S. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007;131:861&#x2013;872. doi: 10.1016/j.cell.2007.11.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2007.11.019</ArticleId><ArticleId IdType="pubmed">18035408</ArticleId></ArticleIdList></Reference><Reference><Citation>Maury Y., C&#xf4;me J., Piskorowski R.A., Salah-Mohellibi N., Chevaleyre V., Peschanski M., Martinat C., Nedelec S. Combinatorial analysis of developmental cues efficiently converts human pluripotent stem cells into multiple neuronal subtypes. Nat. Biotechnol. 2015;33:89&#x2013;96. doi: 10.1038/nbt.3049.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt.3049</ArticleId><ArticleId IdType="pubmed">25383599</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandopulle M.S., Prestil R., Grunseich C., Wang C., Gan L., Ward M. Transcription Factor-Mediated Differentiation of Human iPSCs into Neurons. Curr. Protoc. Cell Biol. 2018;79:e51. doi: 10.1002/cpcb.51.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cpcb.51</ArticleId><ArticleId IdType="pmc">PMC6993937</ArticleId><ArticleId IdType="pubmed">29924488</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancaster M.A., Renner M., Martin C.A., Wenzel D., Bicknell L.S., Hurles M.E., Homfray T., Penninger J.M., Jackson A.P., Knoblich J.A. Cerebral organoids model human brain development and microcephaly. Nature. 2013;501:373&#x2013;379. doi: 10.1038/nature12517.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature12517</ArticleId><ArticleId IdType="pmc">PMC3817409</ArticleId><ArticleId IdType="pubmed">23995685</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y., Inoue H., Wu J.C., Yamanaka S. Induced pluripotent stem cell technology: A decade of progress. Nat. Rev. Drug. Discov. 2017;16:115&#x2013;130. doi: 10.1038/nrd.2016.245.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrd.2016.245</ArticleId><ArticleId IdType="pmc">PMC6416143</ArticleId><ArticleId IdType="pubmed">27980341</ArticleId></ArticleIdList></Reference><Reference><Citation>Penney J., Ralvenius W.T., Tsai L.H. Modeling Alzheimer&#x2019;s disease with iPSC-derived brain cells. Mol. Psychiatry. 2020;25:148&#x2013;167. doi: 10.1038/s41380-019-0468-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41380-019-0468-3</ArticleId><ArticleId IdType="pmc">PMC6906186</ArticleId><ArticleId IdType="pubmed">31391546</ArticleId></ArticleIdList></Reference><Reference><Citation>Laperle A.H., Sances S., Yucer N., Dardov V.J., Garcia V.J., Ho R., Fulton A.N., Jones M.R., Roxas K.M., Avalos P., et al. iPSC modeling of young-onset Parkinson&#x2019;s disease reveals a molecular signature of disease and novel therapeutic candidates. Nat. Med. 2020;26:289&#x2013;299. doi: 10.1038/s41591-019-0739-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-019-0739-1</ArticleId><ArticleId IdType="pubmed">31988461</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferraiuolo L., Maragakis N.J. Mini-Review: Induced pluripotent stem cells and the search for new cell-specific ALS therapeutic targets. Neurosci. Lett. 2021;755:135911. doi: 10.1016/j.neulet.2021.135911.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2021.135911</ArticleId><ArticleId IdType="pubmed">33892003</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramos D.M., Skarnes W.C., Singleton A.B., Cookson M.R., Ward M.E. Tackling neurodegenerative diseases with genomic engineering: A new stem cell initiative from the NIH. Neuron. 2021;109:1080&#x2013;1083. doi: 10.1016/j.neuron.2021.03.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2021.03.022</ArticleId><ArticleId IdType="pmc">PMC8985232</ArticleId><ArticleId IdType="pubmed">33831364</ArticleId></ArticleIdList></Reference><Reference><Citation>Simkin D., Papakis V., Bustos B.I., Ambrosi C.M., Ryan S.J., Baru V., Williams L.A., Dempsey G.T., McManus O.B., Landers J.E., et al. Homozygous might be hemizygous: CRISPR/Cas9 editing in iPSCs results in detrimental on-target defects that escape standard quality controls. Stem Cell Rep. 2022;17:993&#x2013;1008. doi: 10.1016/j.stemcr.2022.02.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stemcr.2022.02.008</ArticleId><ArticleId IdType="pmc">PMC9023783</ArticleId><ArticleId IdType="pubmed">35276091</ArticleId></ArticleIdList></Reference><Reference><Citation>Weisheit I., Kroeger J.A., Malik R., Klimmt J., Crusius D., Dannert A., Dichgans M., Paquet D. Detection of Deleterious On-Target Effects after HDR-Mediated CRISPR Editing. Cell Rep. 2020;31:107689. doi: 10.1016/j.celrep.2020.107689.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2020.107689</ArticleId><ArticleId IdType="pubmed">32460021</ArticleId></ArticleIdList></Reference><Reference><Citation>Rowland L.P., Shneider N.A. Amyotrophic Lateral Sclerosis. N. Engl. J. Med. 2017;377:162&#x2013;172.</Citation><ArticleIdList><ArticleId IdType="pubmed">28700839</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrov D., Mansfield C., Moussy A., Hermine O. ALS Clinical Trials Review: 20 Years of Failure. Are We Any Closer to Registering a New. Treatment? Front. Aging Neurosci. 2017;9:68. doi: 10.3389/fnagi.2017.00068.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2017.00068</ArticleId><ArticleId IdType="pmc">PMC5360725</ArticleId><ArticleId IdType="pubmed">28382000</ArticleId></ArticleIdList></Reference><Reference><Citation>Gowland A., Opie-Martin S., Scott K.M., Jones A.R., Mehta P., Batts C.J., Ellis C.L., Leigh P.N., Shaw C.E., Sreedharan J., et al. Predicting the future of ALS: The impact of demographic change and potential new treatments on the prevalence of ALS in the United Kingdom 2020&#x2013;2116. Amyotroph. Lateral Scler. Front. Degener. 2019;20:264&#x2013;274. doi: 10.1080/21678421.2019.1587629.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2019.1587629</ArticleId><ArticleId IdType="pmc">PMC6567553</ArticleId><ArticleId IdType="pubmed">30961394</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiernan M.C., Vucic S., Talbot K., McDermott C.J., Hardiman O., Shefner J.M., Al-Chalabi A., Huynh W., Cudkowicz M., Talman P., et al. Improving clinical trial outcomes in amyotrophic lateral sclerosis. Nat. Rev. Neurol. 2021;17:104&#x2013;118. doi: 10.1038/s41582-020-00434-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41582-020-00434-z</ArticleId><ArticleId IdType="pmc">PMC7747476</ArticleId><ArticleId IdType="pubmed">33340024</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrews J.A., Jackson C.E., Heiman-Patterson T.D., Bettica P., Brooks B.R., Pioro E.P. Real-world evidence of riluzole effectiveness in treating amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Front. Degener. 2020;21:509&#x2013;518. doi: 10.1080/21678421.2020.1771734.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2020.1771734</ArticleId><ArticleId IdType="pubmed">32573277</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang T., Al Khleifat A., Meurgey J.-H., Jones A., Leigh P.N., Bensimon G., Al-Chalabi A. Stage at which riluzole treatment prolongs survival in patients with amyotrophic lateral sclerosis: A retrospective analysis of data from a dose-ranging study. Lancet Neurol. 2018;17:416&#x2013;422. doi: 10.1016/S1474-4422(18)30054-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(18)30054-1</ArticleId><ArticleId IdType="pmc">PMC5899963</ArticleId><ArticleId IdType="pubmed">29525492</ArticleId></ArticleIdList></Reference><Reference><Citation>Mora J.S., Genge A., Chio A., Estol C.J., Chaverri D., Hern&#xe1;ndez M., Mar&#xed;n S., Mascias J., Rodriguez G.E., Povedano M., et al. Masitinib as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: A randomized clinical trial. Amyotroph. Lateral Scler. Front. Degener. 2020;21:5&#x2013;14. doi: 10.1080/21678421.2019.1632346.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2019.1632346</ArticleId><ArticleId IdType="pubmed">31280619</ArticleId></ArticleIdList></Reference><Reference><Citation>Abe K., Aoki M., Tsuji S., Itoyama Y., Sobue G., Togo M., Hamada C., Tanaka M., Akimoto M., Nakamura K., et al. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: A randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2017;16:505&#x2013;512. doi: 10.1016/S1474-4422(17)30115-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(17)30115-1</ArticleId><ArticleId IdType="pubmed">28522181</ArticleId></ArticleIdList></Reference><Reference><Citation>Lunetta C., Moglia C., Lizio A., Caponnetto C., Dubbioso R., Giannini F., Mat&#xe0; S., Mazzini L., Sabatelli M., Siciliano G., et al. The Italian multicenter experience with edaravone in amyotrophic lateral sclerosis. J. Neurol. 2020;267:3258&#x2013;3267. doi: 10.1007/s00415-020-09993-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-020-09993-z</ArticleId><ArticleId IdType="pubmed">32556567</ArticleId></ArticleIdList></Reference><Reference><Citation>Ganesalingam J., Stahl D., Wijesekera L., Galtrey C., Shaw C.E., Leigh P.N., Al-Chalabi A. Latent cluster analysis of ALS phenotypes identifies prognostically differing groups. PLoS ONE. 2009;4:e7107. doi: 10.1371/journal.pone.0007107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0007107</ArticleId><ArticleId IdType="pmc">PMC2741575</ArticleId><ArticleId IdType="pubmed">19771164</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Chalabi A., Hardiman O., Kiernan M.C., Chi&#xf2; A., Rix-Brooks B., van den Berg L.H. Amyotrophic lateral sclerosis: Moving towards a new classification system. Lancet Neurol. 2016;15:1182&#x2013;1194. doi: 10.1016/S1474-4422(16)30199-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(16)30199-5</ArticleId><ArticleId IdType="pubmed">27647646</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett C.F., Krainer A.R., Cleveland D.W. Antisense Oligonucleotide Therapies for Neurodegenerative Diseases. Annu. Rev. Neurosci. 2019;42:385&#x2013;406. doi: 10.1146/annurev-neuro-070918-050501.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-neuro-070918-050501</ArticleId><ArticleId IdType="pmc">PMC7427431</ArticleId><ArticleId IdType="pubmed">31283897</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller T.M., Cudkowicz M.E., Genge A., Shaw P.J., Sobue G., Bucelli R.C., Chi&#xf2; A., Van Damme P., Ludolph A.C., Glass J.D., et al. Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS. N. Engl. J. Med. 2022;387:1099&#x2013;1110. doi: 10.1056/NEJMoa2204705.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2204705</ArticleId><ArticleId IdType="pubmed">36129998</ArticleId></ArticleIdList></Reference><Reference><Citation>Boros B.D., Schoch K.M., Kreple C.J., Miller T.M. Antisense Oligonucleotides for the Study and Treatment of ALS. Neurotherapeutics. 2022;19:1145&#x2013;1158. doi: 10.1007/s13311-022-01247-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13311-022-01247-2</ArticleId><ArticleId IdType="pmc">PMC9587169</ArticleId><ArticleId IdType="pubmed">35653060</ArticleId></ArticleIdList></Reference><Reference><Citation>Dimos J.T., Rodolfa K.T., Niakan K.K., Weisenthal L.M., Mitsumoto H., Chung W., Croft G.F., Saphier G., Leibel R., Goland R., et al. Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons. Science. 2008;321:1218&#x2013;1221. doi: 10.1126/science.1158799.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1158799</ArticleId><ArticleId IdType="pubmed">18669821</ArticleId></ArticleIdList></Reference><Reference><Citation>Donnelly C.J., Zhang P.W., Pham J.T., Haeusler A.R., Mistry N.A., Vidensky S., Daley E.L., Poth E.M., Hoover B., Fines D.M., et al. RNA toxicity from the ALS/FTD C9ORF72 expansion is mitigated by antisense intervention. Neuron. 2013;80:415&#x2013;428. doi: 10.1016/j.neuron.2013.10.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2013.10.015</ArticleId><ArticleId IdType="pmc">PMC4098943</ArticleId><ArticleId IdType="pubmed">24139042</ArticleId></ArticleIdList></Reference><Reference><Citation>Bilican B., Serio A., Barmada S.J., Nishimura A.L., Sullivan G.J., Carrasco M., Phatnani H.P., Puddifoot C.A., Story D., Fletcher J., et al. Mutant induced pluripotent stem cell lines recapitulate aspects of TDP-43 proteinopathies and reveal cell-specific vulnerability. Proc. Natl. Acad. Sci. USA. 2012;109:5803&#x2013;5808. doi: 10.1073/pnas.1202922109.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1202922109</ArticleId><ArticleId IdType="pmc">PMC3326463</ArticleId><ArticleId IdType="pubmed">22451909</ArticleId></ArticleIdList></Reference><Reference><Citation>Selvaraj B.T., Livesey M.R., Zhao C., Gregory J.M., James O.T., Cleary E.M., Chouhan A.K., Gane A.B., Perkins E.M., Dando O., et al. C9ORF72 repeat expansion causes vulnerability of motor neurons to Ca(2+)-permeable AMPA receptor-mediated excitotoxicity. Nat. Commun. 2018;9:347. doi: 10.1038/s41467-017-02729-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-017-02729-0</ArticleId><ArticleId IdType="pmc">PMC5783946</ArticleId><ArticleId IdType="pubmed">29367641</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith L., Cupid B.C., Dickie B.G.M., Al-Chalabi A., Morrison K.E., Shaw C.E., Shaw P.J. Establishing the UK DNA Bank for motor neuron disease (MND) BMC Genet. 2015;16:84. doi: 10.1186/s12863-015-0236-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12863-015-0236-6</ArticleId><ArticleId IdType="pmc">PMC4501191</ArticleId><ArticleId IdType="pubmed">26170009</ArticleId></ArticleIdList></Reference><Reference><Citation>Hui-Yuen J., McAllister S., Koganti S., Hill E., Bhaduri-McIntosh S. Establishment of Epstein-Barr virus growth-transformed lymphoblastoid cell lines. J. Vis. Exp. 2011;57:3321.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3308597</ArticleId><ArticleId IdType="pubmed">22090023</ArticleId></ArticleIdList></Reference><Reference><Citation>Nam H.-Y., Shim S.-M., Han B.-G., Jeon J.-P. Human lymphoblastoid cell lines: A goldmine for the biobankomics era. Pharmacogenomics. 2011;12:907&#x2013;917. doi: 10.2217/pgs.11.24.</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/pgs.11.24</ArticleId><ArticleId IdType="pubmed">21692620</ArticleId></ArticleIdList></Reference><Reference><Citation>Melo U.S., Leite F.D.S., Costa S., Rosenberg C., Zatz M. A fast method to reprogram and CRISPR/Cas9 gene editing from erythroblasts. Stem Cell Res. 2018;31:52&#x2013;54. doi: 10.1016/j.scr.2018.07.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.scr.2018.07.002</ArticleId><ArticleId IdType="pubmed">30015173</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajesh D., Dickerson S.J., Yu J., Brown M.E., Thomson J.A., Seay N.J. Human lymphoblastoid B-cell lines reprogrammed to EBV-free induced pluripotent stem cells. Blood. 2011;118:1797&#x2013;1800. doi: 10.1182/blood-2011-01-332064.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2011-01-332064</ArticleId><ArticleId IdType="pmc">PMC4081297</ArticleId><ArticleId IdType="pubmed">21708888</ArticleId></ArticleIdList></Reference><Reference><Citation>Barrett R., Ornelas L., Yeager N., Mandefro B., Sahabian A., Lenaeus L., Targan S.R., Svendsen C.N., Sareen D. Reliable generation of induced pluripotent stem cells from human lymphoblastoid cell lines. Stem Cells Transl. Med. 2014;3:1429&#x2013;1434. doi: 10.5966/sctm.2014-0121.</Citation><ArticleIdList><ArticleId IdType="doi">10.5966/sctm.2014-0121</ArticleId><ArticleId IdType="pmc">PMC4250214</ArticleId><ArticleId IdType="pubmed">25298370</ArticleId></ArticleIdList></Reference><Reference><Citation>Hedges E.C., Topp S., Shaw C.E., Nishimura A.L. Generation of six induced pluripotent stem cell lines from patients with amyotrophic lateral sclerosis with associated genetic mutations in either FUS or ANXA11. Stem Cell Res. 2021;52:102246. doi: 10.1016/j.scr.2021.102246.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.scr.2021.102246</ArticleId><ArticleId IdType="pmc">PMC7988463</ArticleId><ArticleId IdType="pubmed">33610019</ArticleId></ArticleIdList></Reference><Reference><Citation>Du Z.-W., Chen H., Liu H., Lu J., Qian K., Huang C.-L., Zhong X., Fan F., Zhang S.-C. Generation and expansion of highly pure motor neuron progenitors from human pluripotent stem cells. Nat. Com. 2015;25:6626. doi: 10.1038/ncomms7626.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms7626</ArticleId><ArticleId IdType="pmc">PMC4375778</ArticleId><ArticleId IdType="pubmed">25806427</ArticleId></ArticleIdList></Reference><Reference><Citation>Mrozek-Gorska P., Buschle A., Pich D., Schwarzmayr T., Fechtner R., Scialdone A., Hammerschmidt W. Epstein-Barr virus reprograms human B lymphocytes immediately in the prelatent phase of infection. Proc. Natl. Acad. Sci. USA. 2019;116:16046&#x2013;16055. doi: 10.1073/pnas.1901314116.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1901314116</ArticleId><ArticleId IdType="pmc">PMC6690029</ArticleId><ArticleId IdType="pubmed">31341086</ArticleId></ArticleIdList></Reference><Reference><Citation>Smatti M.K., Al-Sadeq D.W., Ali N.H., Pintus G., Abou-Saleh H., Nasrallah G.K. Epstein&#x2013;Barr Virus Epidemiology, Serology, and Genetic Variability of LMP-1 Oncogene Among Healthy Population: An Update. Front. Oncol. 2018;8:211. doi: 10.3389/fonc.2018.00211.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fonc.2018.00211</ArticleId><ArticleId IdType="pmc">PMC6008310</ArticleId><ArticleId IdType="pubmed">29951372</ArticleId></ArticleIdList></Reference><Reference><Citation>Jox A., Rohen C., Belge G., Bartnitzke S., Pawlita M., Diehl V., Bullerdiek J., Wolf J. Integration of Epstein-Barr virus in Burkitt&#x2019;s lymphoma cells leads to a region of enhanced chromosome instability. Ann. Oncol. 1997;8:131&#x2013;135. doi: 10.1093/annonc/8.suppl_2.S131.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/annonc/8.suppl_2.S131</ArticleId><ArticleId IdType="pubmed">9209656</ArticleId></ArticleIdList></Reference><Reference><Citation>Janjetovic S., Hinke J., Balachandran S., Aky&#xfc;z N., Behrmann P., Bokemeyer C., Dierlamm J., Penas E.M.M. Non-Random Pattern of Integration for Epstein-Barr Virus with Preference for Gene-Poor Genomic Chromosomal Regions into the Genome of Burkitt Lymphoma Cell Lines. Viruses. 2022;14:86. doi: 10.3390/v14010086.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v14010086</ArticleId><ArticleId IdType="pmc">PMC8781420</ArticleId><ArticleId IdType="pubmed">35062290</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu M., Zhang W.-L., Zhu Q., Yao Y.-Y., Feng Q.-S., Zhang Z., Peng R.-J., Jia W.-H., He G.-P., Feng L., et al. Genome-wide profiling of Epstein-Barr virus integration by targeted sequencing in Epstein-Barr virus associated malignancies. Theranostics. 2019;9:1115&#x2013;1124. doi: 10.7150/thno.29622.</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/thno.29622</ArticleId><ArticleId IdType="pmc">PMC6401403</ArticleId><ArticleId IdType="pubmed">30867819</ArticleId></ArticleIdList></Reference><Reference><Citation>Coppotelli G., Mughal N., Callegari S., Sompallae R., Caja L., Luijsterburg M.S., Dantuma N.P., Moustakas A., Masucci M.G. The Epstein&#x2013;Barr virus nuclear antigen-1 reprograms transcription by mimicry of high mobility group A proteins. Nucleic Acids Res. 2013;41:2950&#x2013;2962. doi: 10.1093/nar/gkt032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkt032</ArticleId><ArticleId IdType="pmc">PMC3597695</ArticleId><ArticleId IdType="pubmed">23358825</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaspar-Maia A., Alajem A., Meshorer E., Ramalho-Santos M. Open chromatin in pluripotency and reprogramming. Nat. Rev. Mol. Cell Biol. 2011;12:36&#x2013;47. doi: 10.1038/nrm3036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrm3036</ArticleId><ArticleId IdType="pmc">PMC3891572</ArticleId><ArticleId IdType="pubmed">21179060</ArticleId></ArticleIdList></Reference><Reference><Citation>Dittmer D.P., Hilscher C.J., Gulley M.L., Yang E.V., Chen M., Glaser R. Multiple pathways for Epstein-Barr virus episome loss from nasopharyngeal carcinoma. Int. J. Cancer. 2008;123:2105&#x2013;2112. doi: 10.1002/ijc.23685.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ijc.23685</ArticleId><ArticleId IdType="pmc">PMC2866115</ArticleId><ArticleId IdType="pubmed">18688856</ArticleId></ArticleIdList></Reference><Reference><Citation>Bjornevik K., Cortese M., Healy B.C., Kuhle J., Mina M.J., Leng Y., Elledge S.J., Niebuhr D.W., Scher A.I., Munger K.L., et al. Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis. Science. 2022;375:296&#x2013;301. doi: 10.1126/science.abj8222.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abj8222</ArticleId><ArticleId IdType="pubmed">35025605</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith B.N., Topp S.D., Fallini C., Shibata H., Chen H.-J., Troakes C., King A., Ticozzi N., Kenna K.P., Soragia-Gkazi A., et al. Mutations in the vesicular trafficking protein annexin A11 are associated with amyotrophic lateral sclerosis. Sci. Trans. Med. 2017;9:eaad9157. doi: 10.1126/scitranslmed.aad9157.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aad9157</ArticleId><ArticleId IdType="pmc">PMC6599403</ArticleId><ArticleId IdType="pubmed">28469040</ArticleId></ArticleIdList></Reference><Reference><Citation>Teyssou E., Muratet F., Amador M.-D., Ferrien M., Lautrette G., Machat S., Boill&#xe9;e S., Larmonier T., Saker S., Leguern E., et al. Genetic screening of ANXA11 revealed novel mutations linked to Amyotrophic Lateral Sclerosis. Neurobiol. Aging. 2021;99:e11&#x2013;e102. doi: 10.1016/j.neurobiolaging.2020.10.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2020.10.015</ArticleId><ArticleId IdType="pubmed">33218681</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang K., Liu Q., Liu K., Shen D., Tai H., Shu S., Ding Q., Fu H., Liu S., Wang Z., et al. ANXA11 mutations prevail in Chinese ALS patients with and without cognitive dementia. Neurol. Genet. 2018;4:e237. doi: 10.1212/NXG.0000000000000237.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/NXG.0000000000000237</ArticleId><ArticleId IdType="pmc">PMC5963931</ArticleId><ArticleId IdType="pubmed">29845112</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper-Knock J., Moll T., Ramesh T., Castelli L., Beer A., Robins H., Fox I., Niedermoser I., Van Damme P., Moisse M., et al. Mutations in the Glycosyltransferase Domain of GLT8D1 Are Associated with Familial Amyotrophic Lateral Sclerosis. Cell Rep. 2019;26:2298&#x2013;2306.e5. doi: 10.1016/j.celrep.2019.02.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2019.02.006</ArticleId><ArticleId IdType="pmc">PMC7003067</ArticleId><ArticleId IdType="pubmed">30811981</ArticleId></ArticleIdList></Reference><Reference><Citation>Fat S.C.M., McCann E.P., Williams K.L., Henden L., Twine N.A., Bauer D.C., Pamphlett R., Kiernan M.C., Rowe D.B., Nicholson G.A., et al. Genetic analysis of GLT8D1 and ARPP21 in Australian familial and sporadic amyotrophic lateral sclerosis. Neurobiol. Aging. 2021;101:e9&#x2013;e297.</Citation><ArticleIdList><ArticleId IdType="pubmed">33581934</ArticleId></ArticleIdList></Reference><Reference><Citation>Li W., Liu Z., Sun W., Yuan Y., Hu Y., Ni J., Jiao B., Fang L., Li J., Shen L., et al. Mutation analysis of GLT8D1 and ARPP21 genes in amyotrophic lateral sclerosis patients from mainland China. Neurobiol. Aging. 2020;85:156.e1&#x2013;156.e4. doi: 10.1016/j.neurobiolaging.2019.09.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2019.09.013</ArticleId><ArticleId IdType="pubmed">31653410</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamas N.J., Roybon L. Harnessing the Potential of Human Pluripotent Stem Cell-Derived Motor Neurons for Drug Discovery in Amyotrophic Lateral Sclerosis: From the Clinic to the Laboratory and Back to the Patient. Front. Drug Discov. 2021;1:773424. doi: 10.3389/fddsv.2021.773424.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fddsv.2021.773424</ArticleId></ArticleIdList></Reference><Reference><Citation>Richard J.-P., Maragakis N.J. Induced pluripotent stem cells from ALS patients for disease modeling. Brain Res. 2015;1607:15&#x2013;25. doi: 10.1016/j.brainres.2014.09.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2014.09.017</ArticleId><ArticleId IdType="pmc">PMC4362997</ArticleId><ArticleId IdType="pubmed">25223906</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo W., Fumagalli L., Prior R., Van Den Bosch L. Current Advances and Limitations in Modeling ALS/FTD in a Dish Using Induced Pluripotent Stem Cells. Front. Neurosci. 2017;11:671. doi: 10.3389/fnins.2017.00671.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2017.00671</ArticleId><ArticleId IdType="pmc">PMC5733489</ArticleId><ArticleId IdType="pubmed">29326542</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo W., Naujock M., Fumagalli L., Vandoorne T., Baatsen P., Boon R., Ordov&#xe1;s L., Patel A., Welters M., Vanwelden T., et al. HDAC6 inhibition reverses axonal transport defects in motor neurons derived from FUS-ALS patients. Nat. Com. 2017;8:861. doi: 10.1038/s41467-017-00911-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-017-00911-y</ArticleId><ArticleId IdType="pmc">PMC5636840</ArticleId><ArticleId IdType="pubmed">29021520</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu M.-L., Zang T., Zhang C.-L. Direct Lineage Reprogramming Reveals Disease-Specific Phenotypes of Motor Neurons from Human ALS Patients. Cell Rep. 2016;14:115&#x2013;128. doi: 10.1016/j.celrep.2015.12.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2015.12.018</ArticleId><ArticleId IdType="pmc">PMC4706770</ArticleId><ArticleId IdType="pubmed">26725112</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu X., Chen J., Liu W., Li X., Chen Q., Liu T., Gao S., Deng M. The fused in sarcoma protein forms cytoplasmic aggregates in motor neurons derived from integration-free induced pluripotent stem cells generated from a patient with familial amyotrophic lateral sclerosis carrying the FUS-P525L mutation. Neurogen. 2015;16:223&#x2013;231. doi: 10.1007/s10048-015-0448-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10048-015-0448-y</ArticleId><ArticleId IdType="pubmed">25912081</ArticleId></ArticleIdList></Reference><Reference><Citation>Ichiyanagi N., Fujimori K., Yano M., Ishihara-Fujisaki C., Sone T., Akiyama T., Okada Y., Akamatsu W., Matsumoto T., Ishikawa M., et al. Establishment of In Vitro FUS-Associated Familial Amyotrophic Lateral Sclerosis Model Using Human Induced Pluripotent Stem Cells. Stem Cell Rep. 2016;6:496&#x2013;510. doi: 10.1016/j.stemcr.2016.02.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stemcr.2016.02.011</ArticleId><ArticleId IdType="pmc">PMC4834049</ArticleId><ArticleId IdType="pubmed">26997647</ArticleId></ArticleIdList></Reference><Reference><Citation>Garone M.G., Birsa N., Rosito M., Salaris F., Mochi M., de Turris V., Nair R.R., Cunningham T.J., Fisher E.M.C., Morlando M., et al. ALS-related FUS mutations alter axon growth in motoneurons and affect HuD/ELAVL4 and FMRP activity. Commun. Biol. 2021;4:1025. doi: 10.1038/s42003-021-02538-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s42003-021-02538-8</ArticleId><ArticleId IdType="pmc">PMC8410767</ArticleId><ArticleId IdType="pubmed">34471224</ArticleId></ArticleIdList></Reference><Reference><Citation>Akiyama T., Suzuki N., Ishikawa M., Fujimori K., Sone T., Kawada J., Funayama R., Fujishima F., Mitsuzawa S., Ikeda K., et al. Aberrant axon branching via Fos-B dysregulation in FUS-ALS motor neurons. EBioMedicine. 2019;45:362&#x2013;378. doi: 10.1016/j.ebiom.2019.06.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2019.06.013</ArticleId><ArticleId IdType="pmc">PMC6642224</ArticleId><ArticleId IdType="pubmed">31262712</ArticleId></ArticleIdList></Reference><Reference><Citation>Dittlau K.S., Krasnow E.N., Fumagalli L., Vandoorne T., Baatsen P., Kerstens A., Giacomazzi G., Pavie B., Rossaert E., Beckers J., et al. Human motor units in microfluidic devices are impaired by FUS mutations and improved by HDAC6 inhibition. Stem Cell Rep. 2021;16:2213&#x2013;2227. doi: 10.1016/j.stemcr.2021.03.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stemcr.2021.03.029</ArticleId><ArticleId IdType="pmc">PMC8452598</ArticleId><ArticleId IdType="pubmed">33891869</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>